Neuromodulation Devices for Migraine
Non-invasive neuromodulation devices offer drug-free options for migraine prevention and acute treatment. Four FDA-cleared devices target different neural pathways — the trigeminal nerve, vagus nerve, occipital nerves, or cortical neurons. Evidence quality varies considerably. These devices are best positioned as adjuncts to pharmacotherapy or as options for patients who cannot tolerate, prefer to avoid, or have contraindications to medications.
Bottom Line
- Cefaly (eTNS): Best evidence for prevention among devices. FDA-cleared for both prevention and acute treatment. Worn 20 min/day on the forehead.
- SpringTMS / sTMS (single-pulse TMS): FDA-cleared for acute and preventive treatment of migraine with aura. Placed on occiput.
- gammaCore (nVNS): Non-invasive vagus nerve stimulation. FDA-cleared for acute treatment of episodic migraine and cluster headache. Preventive use is off-label.
- Nerivio (REN): Remote electrical neuromodulation applied to the upper arm. FDA-cleared for acute migraine treatment. Convenient smartphone-controlled.
- All devices are well-tolerated with minimal side effects; main barriers are cost, insurance coverage, and modest effect sizes
Cefaly (External Trigeminal Nerve Stimulation)
An electrode placed on the forehead over the supraorbital/supratrochlear branches of the trigeminal nerve (V1). Delivers precise micro-impulses to modulate trigeminal sensory processing.
Evidence
EPIC trial (Schoenen 2013): 67 patients with episodic migraine randomized to active Cefaly or sham device for 3 months of daily 20-minute sessions.
- Change in monthly migraine days: -2.1 (active) vs -0.3 (sham), p=0.023
- ≥50% responder rate: 38% vs 12%
Acute treatment (Chou 2019): Prospective trial of Cefaly in acute setting (60-minute session at onset).
- Pain-free at 2 hours: 25%; pain relief at 2 hours: 56%
- Comparable to some oral acute medications
Practical Use
Cefaly: How to Use
- Prevention: 20-minute session daily (PREVENT mode: 60 Hz, lower intensity)
- Acute: 60-minute session at headache onset (ACUTE mode: 100 Hz, higher intensity)
- Adhesive electrode placed on the forehead centered above the nose
- Sensation: tingling/paresthesia on the forehead; intensity is adjustable
- Electrodes are replaced every ~15-20 sessions
- Can be used alongside any medication without interaction
Single-Pulse TMS (sTMS / SpringTMS)
A handheld device placed on the occiput that delivers a single magnetic pulse to disrupt cortical spreading depression — the electrophysiologic substrate of migraine aura.
Evidence
ESPOUSE trial (Starling 2018): Open-label prospective study of 263 patients using sTMS for both acute and preventive treatment over 3 months.
- Prevention: Mean reduction of -2.75 migraine days/month
- ≥50% responder rate: 46%
- Open-label design limits interpretation; randomized sham-controlled data is limited
Lipton et al. (2010): Randomized sham-controlled trial in migraine with aura (acute treatment). Pain-free at 2 hours: 39% vs 22% (p=0.018).
Practical Use
- Acute: 3 pulses at headache/aura onset; can repeat every 15 minutes (max 9 pulses/attack)
- Prevention: 4 pulses twice daily
- Placed on the occiput; each pulse lasts <1 second
- Theoretically most effective for migraine with aura (targets cortical spreading depression)
TMS Contraindications
- Implanted metallic or electronic devices in the head (cochlear implants, deep brain stimulators, metallic stents)
- Epilepsy or history of seizures (TMS can lower seizure threshold, though single-pulse TMS risk is very low)
- Pacemakers or implantable cardioverter-defibrillators (relative contraindication)
gammaCore (Non-Invasive Vagus Nerve Stimulation)
A handheld device applied to the neck over the vagus nerve that delivers electrical stimulation. The vagus nerve modulates trigeminocervical complex activity and central pain processing.
Evidence
PRESTO trial (Tassorelli 2018): Randomized sham-controlled trial of nVNS for acute episodic migraine (248 patients).
- Pain-free at 2 hours: 12.7% vs 4.2% (p=0.012)
- Modest but statistically significant acute effect
EVENT study (Silberstein 2016): Randomized trial of nVNS for migraine prevention. No significant difference in migraine days vs sham in the primary analysis; a post-hoc analysis of chronic migraine subgroup showed benefit.
Cluster headache (ACT trials): Stronger evidence exists for acute treatment of episodic cluster headache, where gammaCore is FDA-cleared.
Practical Use
- Acute: Two 2-minute stimulations at headache onset; can repeat after 20 minutes
- Prevention (off-label for migraine): Two 2-minute stimulations twice daily
- Applied to the right side of the neck over the vagus nerve; gel required for conductance
- Well-tolerated; main complaints are neck discomfort, tingling, and hoarseness during stimulation
Nerivio (Remote Electrical Neuromodulation)
A wearable armband that delivers electrical stimulation to the upper arm, activating conditioned pain modulation (CPM) — an endogenous pain inhibitory pathway where a non-painful stimulus at a remote body site reduces pain perception.
Evidence
Yarnitsky et al. (2017): Randomized sham-controlled trial in 252 episodic migraine patients.
- Pain-free at 2 hours: 37% vs 18% (p=0.002)
- Pain relief at 2 hours: 67% vs 39%
Adolescent data (Hershey 2021): FDA-cleared for acute treatment in patients ≥12 years based on positive open-label data.
Practical Use
- Applied to the upper arm at migraine onset; 45-minute session
- Controlled via smartphone app; intensity is patient-adjustable
- Sensation should be strong but not painful
- Prescribed through the app; no in-office setup needed
- Currently cleared for acute treatment only; not for prevention
Device Comparison
| Device | Target | FDA Indication | Acute Evidence | Preventive Evidence |
|---|---|---|---|---|
| Cefaly | Trigeminal (V1) | Acute + Prevention | Moderate | Best among devices (EPIC trial) |
| sTMS (SpringTMS) | Occipital cortex | Acute + Prevention | Positive (aura) | Open-label only (ESPOUSE) |
| gammaCore | Vagus nerve | Acute (migraine + cluster) | Modest (PRESTO) | Negative primary analysis |
| Nerivio | Upper arm (CPM pathway) | Acute only | Positive | Not studied |
When to Consider Neuromodulation
- Medication intolerance or contraindications — pregnancy, multiple drug sensitivities, hepatic/renal disease
- Patient preference for drug-free approach (complementary to lifestyle modifications)
- Adjunct to medications — can be added to any preventive or acute regimen without pharmacologic interactions
- Adolescents — device therapy avoids medication side effects in young patients
- Medication overuse headache — devices provide an acute treatment option that does not contribute to MOH
- Realistic expectations: Effect sizes are generally smaller than pharmacotherapy. Most useful as part of a multi-modal strategy, not as sole treatment in moderate-severe migraine.
References
- Schoenen J, et al. Migraine prevention with a supraorbital transcutaneous stimulator (EPIC trial). Neurology. 2013;80(8):697-704.
- Chou DE, et al. Acute migraine therapy with external trigeminal neurostimulation (ACME). Cephalalgia. 2019;39(1):3-14.
- Starling AJ, et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE). Cephalalgia. 2018;38(6):1038-1048.
- Lipton RB, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura. Lancet Neurol. 2010;9(4):373-380.
- Tassorelli C, et al. Noninvasive vagus nerve stimulation as acute therapy for migraine (PRESTO). Neurology. 2018;91(4):e364-e373.
- Yarnitsky D, et al. Remote electrical neuromodulation (REN) for the acute treatment of migraine. Headache. 2019;59(8):1240-1252.